A5047805762- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Biosimilars and Bioanalytical Methods
- Blood groups and transfusion
- Chromatin Remodeling and Cancer
- Acute Myeloid Leukemia Research
- COVID-19 Impact on Reproduction
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Insect Resistance and Genetics
- Lymphoma Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Immunotherapy and Immune Responses
- Nuclear Structure and Function
- Malaria Research and Control
- Cancer Mechanisms and Therapy
- International Relations in Latin America
Icahn School of Medicine at Mount Sinai
2022-2025
Tisch Hospital
2023-2025
Dana-Farber Cancer Institute
2024
Mount Sinai Hospital
2022-2024
University of Milan
1987-2024
Cornell University
2014-2023
Tisch Cancer Institute
2023
Weill Cornell Medicine
2016-2023
Presbyterian Hospital
2011-2023
New York Hospital Queens
2012-2022
Abstract BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all and their risk factors, evaluated the impact of infection prophylaxis patients treated with BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, two infection-related deaths during deep remissions. Most (84%) occurred disease The cumulative probability...
B-cell maturation antigen (BCMA)-directed chimeric receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food Drug Administration-approved BCMA-directed CAR T products. However, despite high initial response rates, most eventually relapse. The outcomes of disease recurrence after have not been comprehensively studied, such an analysis would help define optimal treatment strategies. We analyzed the...
Chimeric antigen receptor T cell (CAR-T) therapies are Food and Drug Administration (FDA)-approved for patients with triple refractory multiple myeloma (MM). Real-world access to CAR-T therapy remains challenging owing supply chain limitations impacting manufacturing. The goal of this study was evaluate the extent issue how major centers handling challenges manufacturing slot allocation. MM physician leaders at each treatment center across United States were surveyed. We received responses...
Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, may therefore be particularly susceptible COVID-19. Here, we report outcomes risk factors for serious in patients treated at five large academic centers New York City spring of 2020, during which it was global epicenter SARS-CoV-2 pandemic. Of 100 (male 58%; median age 68) diagnosed COVID-19, 75 were admitted; these, 13 (17%) placed on invasive mechanical ventilation, 22 (29%)...
T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), leading to the approval of 2 CAR products numerous BiAb trials. Data on outcomes after relapse following BiAbs are urgently required develop strategies for sequencing salvage therapies. We identified 58 progressing a trial at Mount Sinai Hospital. Progression-free survival (PFS)...
First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but contribution pathogenic germline variants (PGV) in hereditary cancer genes to and outcomes is not well characterized. To address this, we analyzed exomes two independent cohorts 895 786 myeloma. PGVs were identified 8.6% Discovery cohort 11.5% Replication cohort, a notable presence high- or moderate-penetrance (associated autosomal dominant predisposition) DNA repair (3.6% 4.1%, respectively)....
B-cell maturation antigen (BCMA)-targeting chimeric receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion after infusion has been shown to inform depth duration response (DoR), but measuring this process remains investigational. This multicenter study describes kinetics prognostic impact absolute lymphocyte count (ALC) first 15 days 156 patients with relapsed MM treated BCMA-targeting...
Abstract Importance New York City is a global epicenter for the SARS-CoV-2 outbreak with significant number of individuals infected by virus. Patients multiple myeloma have compromised immune system, due to both disease and anti-myeloma therapies, may therefore be particularly susceptible coronavirus 2019 (COVID-19); however, there limited information guide clinical management. Objective To assess risk factors outcomes COVID-19 in patients myeloma. Design Case-series. Setting Five large...
We assessed the safety, efficacy, maximum tolerated dose (MTD), and recommended phase 2 (RP2D) of selinexor, a first in class oral selective inhibitor nuclear export (100 mg once weekly [QW] or 60 twice weekly), combination with daratumumab (16 mg/kg per label) dexamethasone (40 QW) (SDd) patients relapsed refractory multiple myeloma (RRMM). Thirty-four (median prior therapies, 3 [range, 2-10]) were enrolled; MM was to proteasome (PI) 85%, immunomodulatory agent (IMiD) 76%, both 74%, 6%...
Proteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor nuclear export (SINE) compound, in preclinical models multiple myeloma (MM).
A double-blind, placebo-controlled, parallel-group, multicentre study was conducted to evaluate the efficacy of pentoxifylline (Trental) in patients with multi-infarct dementia (MID) according DSM-III-R criteria. Men and women aged 45 years or older, a Hachinski Ischemia Scale score > = 7 Mini Mental State Examination (MMSE) 10-25 at entry, computed tomographic evidence vascular disease were enrolled. total 289 randomised receive either oral 400 mg t.i.d. placebo for 9 months, assessed every...
Background: While chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation (BCMA) have shown deep and durable responses in RRMM, new targets are needed as most patients (pts) relapse. GPRC5D, an orphan expressed on MM cells with limited expression other tissues, is a promising therapeutic target for MM. Aims: To present safety efficacy from the Part A dose escalation of CC-95266-MM-001 (NCT04674813), phase 1, first-in-human, multicenter, open-label study BMS-986393...
Background/Objectives: Chimeric antigen receptor T-cell therapy (CAR-T) has become a key treatment option for relapsed/refractory multiple myeloma (RRMM), but factors impairing fitness may diminish efficacy. Our exploratory analysis aimed to evaluate the impact of prior with selinexor-containing regimen on CAR-T outcomes RRMM patients. Methods: Data this retrospective cohort study were sourced from electronic medical records at two US academic centers. Kaplan-Meier estimates assessed...
Epstein-Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common potentially fatal complications after allogeneic transplantation with mismatched donors T-cell depletion. Haplo-cord combines a UCB graft third-party cells. Conditioning involves thymoglobulin. EBV PTLD were in initial patients. As of March 2017, we administered prophylactic dose rituximab 375 mg/m2 pre-transplant. Among 147 patients who did not receive rituximab, the cumulative...
Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed refractory patients with multiple myeloma (MM). However, there is limited evidence on treatment patterns effectiveness of daratumumab in the real-world setting, particularly first line (1 L). This study aimed to describe clinical outcomes initiating different lines therapy.A retrospective chart review adult MM between November 2015...
TPS8063 Background: Autologous CAR-T cell therapies have shown significant benefit in the treatment of adults with relapsed/refractory multiple myeloma (r/r MM). However, these may inherent challenges, including functional deficiencies patient’s T cells, that could yield an inconsistent or impaired product, as well require extended time and complexity manufacturing, thereby limiting patient access potentially requiring bridging therapy. CB-011 is allogeneic, off-the-shelf anti-BCMA therapy...
Background The increasing use of anti-CD38 monoclonal antibodies (αCD38 mAbs) for newly diagnosed or early relapsed multiple myeloma (MM), especially in non-transplant eligible patients, may lead to more patients developing αCD38 mAb-refractory disease earlier the treatment course with fewer options. Patients and methods We analyzed efficacy safety selinexor-based triplets (selinexor+dexamethasone [Sd] plus pomalidomide [SPd, n=23], bortezomib [SVd, n=16] carfilzomib (SKd, n=23]) a subset...